The discussion regarding benefits and harms of erythropoiesis-stimulating agents (ESAs) in oncology is ongoing, with conflicting data from numerous studies. The review by Hadland and Longmore on this topic covers the existing literature in an organized, detailed and unbiased manner. Of particular interest is the discussion on potential mechanisms leading to tumor progression and decreased survival in oncology patients treated with ESAs. The article is worth reading.

– alice Maniatis